TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10780142
Drug: Child in
Normalized name: Pro Comfort Child Inhaler Spacer Chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child in remission from cancer and no longer undergoing treatment (RCL)
Study: 10780142
Drug: Child in
Normalized name: Pro Comfort Child Inhaler Spacer Chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child in remission and still undergoing treatment (RCTL)
Study: 1471706
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol treatment for 6 weeks
Study: 6718766
Drug: Neurotensin infusion
Normalized name: neurotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotensin infusion at 3 pmol X kg‐1 X min‐1 for 4 h
Study: 6718766
Drug: Neurotensin infusion
Normalized name: neurotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotensin infusion
Study: 23096033
Drug: Cytoflavin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (2 tablets twice a day) and standard therapy (acetylsalicylic acid and antihypertensive drugs)
Study: 23096033
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (acetylsalicylic acid and antihypertensive drugs)
Study: 16802767
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg daily)
Study: 17623754
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 microg per day in two doses)
Study: 12124481
Drug: AGAb bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGAb bone marrow immunoscintigraphy (370 MBq of (99m)Tc labelled anti‐NCA‐95 antigranulocyte antibodies)
Study: 7825764
Drug: Concurrent review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent review classification
Study: 385399
Drug: mianserin 30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 30‐60 mg daily
Study: 385399
Drug: diazepam 15‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 15‐30 mg daily
Study: 25840004
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group received an intranasal dose of 'serotonin' (placebo) prior to the second stress test.
Study: 23827259
Drug: Low-dose naltrexone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naltrexone (192 mg)
Study: 23827259
Drug: High-dose naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naltrexone (384 mg)
Study: 17692720
Drug: Varenicline 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 0.25 mg BID
Study: 17692720
Drug: Varenicline 0.5
Normalized name: varenicline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 0.5 mg BID
Study: 17692720
Drug: Varenicline (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (all doses)
Study: 11281235
Drug: Calcium-blocking drugs
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-blocking drugs
Study: 19248130
Drug: Sequential monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential monotherapy
Study: 11281235
Drug: ACE inhibitors,
Normalized name: ACE INHIBITORS, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors, calcium-blocking drugs, diuretics
Study: 4907514
Drug: Ampicillin, 1
Normalized name: Ampicillin, 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 1 g. four times a day for 28 days
Study: 4907514
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in identical capsules for 28 days
Study: 23725973
Drug: L-carnitine-containing peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine-containing peritoneal dialysis solution (0.1%, 2 g/bag)
Study: 23725973
Drug: Standard glucose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose-based solution (1.5% or 2.5%)
Study: 23725973
Drug: L-carnitine-containing solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine-containing solution
Study: 23725973
Drug: Standard glucose-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard glucose-based solution
Study: 17615905
Drug: Zinc plus
Normalized name: Zinc plus Copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc plus multivitamin syrup
Study: 17615905
Drug: Multivitamin syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin syrup
Study: 12926799
Drug: Beta-carotene (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (25 mg) twice daily for 36 months
Study: 12926799
Drug: Placebo (saccharose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saccharose capsules)
Study: 12213867
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 mg
Study: 10868832
Drug: Nateglinide 180
Normalized name: nateglinide 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 180 mg
Study: 20446252
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel (10 cc of 2% lidocaine)
Study: 20446252
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block (10 cc of 1% lidocaine solution)
Study: 20446252
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 cc of ultrasound gel)
Study: 1833126
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral contraceptives (20 micrograms ethinyl estradiol and 150 micrograms desogestrel per day)
Study: 1833126
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral contraceptives (50 micrograms ethinyl estradiol and 125 micrograms desogestrel per day)
Study: 1833126
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before drug ingestion)
Study: 6285744
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (1.25 mg daily, orally)
Study: 6285744
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol (5 gm ointment, 3 mg E2, applied each evening)
Study: 26245498
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRHa) goserelin, which causes a net decrease in sex-steroid levels.
Study: 26245498
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone agonist (GnRHa) goserelin
Study: 25267532
Drug: Carers' assessment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carers' assessment, skills and information sharing (C) intervention + treatment as usual (TAU)
Study: 17287932
Drug: Probiotic Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Escherichia coli Nissle 1917 (EcN) solution, 1-3 ml per day (10^8 viable EcN cells per millilitre)
Study: 17287932
Drug: Probiotic Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Escherichia coli Nissle 1917 (EcN) solution
Study: 12811371
Drug: Serotonin treatment
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin treatment
Study: 10556126
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg by mouth, every 8 hours for 3 days)
Study: 6177441
Drug: Aprotinin therapy
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin therapy added to hypovolaemia treatment
Study: 30865917
Drug: Oral targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral targeted therapy or chemotherapy
Study: 28461543
Drug: Anxiety levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiety levels (measured daily with a visual analog scale)
Study: 28461543
Drug: Sedative exposure
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative exposure (daily sedation intensity score and sedative dose frequency)
Study: 23806013
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list group reassessed after five weeks, then randomly assigned to one of the two treatments.
Study: 10764365
Drug: Nurse prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse prescriptions
Study: 10764365
Drug: Doctor prescriptions
Normalized name: Doctor's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doctor prescriptions
Study: 8968035
Drug: Clodronate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1600 mg daily by mouth
Study: 1293650
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg) - two doses (the previous night and before surgery)
Study: 1293650
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) - two doses (the previous night and before surgery)
Study: 1293650
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg) - the night prior to surgery
Study: 1293650
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg) - the night before
Study: 1293650
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg) - two doses (the previous night and before surgery)
Study: 6085358
Drug: Nifedipine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (1.0 mg intravenous)
Study: 6085358
Drug: Nitrendipine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (1.0 mg intravenous)
Study: 26773917
Drug: Pharmacotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy plus physical exercise (n=7)
Study: 26773917
Drug: Only pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only pharmacotherapy (n=7)
Study: 22588010
Drug: Brief intensified
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intensified cognitive behavioral therapy (CBT) and/or pharmacotherapy
Study: 12239942
Drug: 5‐isosorbide mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐isosorbide mononitrate (80 mg/day)
Study: 2147621
Drug: 40‐80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40‐80 mg ketanserin daily for 4 months
Study: 30487058
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin therapy for primary prevention of atherosclerotic events
Study: 26072302
Drug: Periarticular anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular anesthesia (ropivacaine 1% 20 mL)
Study: 26072302
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous analgesia alone
Study: 24246210
Drug: Imidafenacin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidafenacin 0.1 mg twice daily for 12 weeks
Study: 24246210
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg once daily for 12 weeks
Study: 12473833
Drug: d4T (stavudine)
Normalized name: STAVUDINE (d4T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d4T (stavudine) in combination with lamivudine and indinavir
Study: 12473833
Drug: ZDV (zidovudine)
Normalized name: ZDV
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZDV (zidovudine) in combination with lamivudine and indinavir
Study: 510206
Drug: VAC chemotherapy
Normalized name: VAC-52150
DrugBank: VAC-52150 (DB17781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC chemotherapy (vincristin, adriamycin, cyclophosphamide)
Study: 510206
Drug: FMC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMC chemotherapy (fluorouracil, methotrexate, cyclophosphamide)
Study: 31418908
Drug: e-CBT (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-CBT (cognitive behavioural therapy with an email-based recording and reminding system for 20 days)
Study: 31418908
Drug: s-CBT (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-CBT (cognitive behavioural therapy with a sticky note reminder for 20 days)
Study: 20179692
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (diet, exercise, laxatives)
Study: 15042229
Drug: Insecticide-treated curtains
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insecticide-treated curtains (ITC) provided to half the population in 1994, with re-treatment or replacement annually.
Study: 3518625
Drug: Ampicillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (4 g)
Study: 24396842
Drug: Laser-Lok type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-Lok type implants (n = 39)
Study: 24396842
Drug: Non-Laser-Lok type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Laser-Lok type implants (n = 39)
Study: 20203244
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate, 200 microg twice a day for 3 days after 14 days of oxymetazoline
Study: 20203244
Drug: Intranasal oxymetazoline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxymetazoline, 200 microg three times a day for 14 days
Study: 20203244
Drug: Oral prazosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prazosin, 1 mg
Study: 17653243
Drug: Angiotensin inhibition
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin inhibition (ACE inhibitor or angiotensin receptor blocker)
Study: 15799687
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg twice weekly, alone or in combination with methotrexate
Study: 12553620
Drug: Prompt‐L‐Pop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt‐L‐Pop
Study: 369515
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg ethynodiol diacetate + 0.1 mg mestranol ('Ovulen')
Study: 29189955
Drug: Intra‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐ and peri‐articular blood injection (Group A)
Study: 29189955
Drug: Peri‐articular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri‐articular injection alone (Group B)
Study: 24828894
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (perindopril ± indapamide)
Study: 11840080
Drug: CMV gB/MF59
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV gB/MF59 vaccine (20 microg)
Study: 8907724
Drug: Twice-daily enteric-coated
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily enteric-coated sodium valproate tablets
Study: 8907724
Drug: Twice-daily controlled
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily controlled release tablets (Epilim Chrono)
Study: 8907724
Drug: Once-daily controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily controlled release tablets (Epilim Chrono)
Study: 30360014
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg under fasted conditions
Study: 30360014
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg under fed conditions
Study: 28566209
Drug: Half-dose TKI
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose TKI therapy (imatinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg twice daily) for 12 months
Study: 26475066
Drug: Early salvage
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early salvage radiation therapy
Study: 26475066
Drug: 3-dimensional conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dimensional conformal radiation therapy
Study: 29145540
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg daily)
Study: 10422927
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg intravenous fluid
Study: 10422927
Drug: 2 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml/kg intravenous fluid
Study: 8665556
Drug: Apomorphine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine 1.5 mg
Study: 15134988
Drug: Apomorphine 3
Normalized name: apomorphine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine 3 mg
Study: 1688044
Drug: Oxatomide gel
Normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide gel at 5%
Study: 1688044
Drug: Dechlorpheniramine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dechlorpheniramine cream at 1%
Study: 6642380
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg orally in the evening and 400 mg intramuscularly two hours prior to induction of anesthesia
Study: 18451780
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific medication (Control)
Study: 31393399
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg or Anastrozole 1 mg once a day
Study: 19095871
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine (basal 8 mL/h, bolus 4 mL)
Study: 19095871
Drug: 0.4% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% ropivacaine (basal 4 mL/h, bolus 2 mL)
Study: 11116103
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 mg)
Study: 8322135
Drug: Open vaginal
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open vaginal vault method with preoperative cefonicid administration
Study: 3524970
Drug: Diflunisal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500 mg twice daily)
Study: 3524970
Drug: Phenylbutazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (200 mg twice daily)
Study: 27863806
Drug: ABT‐493 25-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐493 25-800 mg (single doses)
Study: 27863806
Drug: ABT‐493 200-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐493 200-800 mg (multiple doses)
Study: 27863806
Drug: ABT‐493 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐493 (all doses)
Study: 24950985
Drug: Trebananib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib (15 mg/kg) plus weekly intravenous paclitaxel (80 mg/m²)
Study: 24950985
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus weekly intravenous paclitaxel (80 mg/m²)
Study: 24950985
Drug: Trebananib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib (15 mg/kg)
Study: 17087311
Drug: Vitamin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin treatment
Study: 26423732
Drug: Garlic treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic treatment
Study: 19417716
Drug: MDMA (ecstasy)
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (ecstasy) administration in humans
Study: 19417716
Drug: MDMA (ecstasy)
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (ecstasy) administration in squirrel monkeys
Study: 19417716
Drug: MDMA (ecstasy)
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (ecstasy) administration in both species
Study: 17853767
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Tetracycline and external application of Cuochuangping Ointment
Study: 11182474
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tiagabine
Study: 9164315
Drug: Eptifibatide 135
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide 135 micrograms/kg bolus followed by 0.5 microgram kg‐1 min‐1 infusion for 20‐24 h
Study: 9164315
Drug: Eptifibatide 135
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide 135 micrograms/kg bolus followed by 0.75 microgram kg‐1 min‐1 infusion for 20‐24 h
Study: 9164315
Drug: Eptifibatide treatment
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide treatment
Study: 24666767
Drug: IV clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV clonidine 2 mcg·kg(‐1)
Study: 24666767
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl 2 mcg·kg(‐1)
Study: 22092081
Drug: Low-dose double-blind
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose double-blind placebo-controlled food challenge (DBPCFC) using a standardized vehicle with eight titrated protein doses from 3 μg to 1 g
Study: 30582717
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.05% ointment
Study: 1444880
Drug: Acetyl levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetyl levocarnitine hydrochloride (2.5 g/d for 3 months followed by 3 g/d for 3 months)
Study: 20012550
Drug: Anti-TNF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF treatment (group 1, n=23)
Study: 20012550
Drug: NSAIDs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs treatment (group 2, n=24)
Study: 2752716
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg lomefloxacin, given orally twice daily for 2 weeks
Study: 2752716
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to four subjects